Latest News

Whenever the term, HER2, is mentioned, people immediately think, “breast cancer.” With the regulatory approvals of trastuzumab and ado-trastuzumab emtansine, oncologists now have multiple approaches to address HER2 amplified breast cancers. However, HER2 overexpression in gastric cancer has also led to a demonstration of trastuzumab treatment benefit in that disease. We’ve often heard about HER2 […]

San Francisco, CA (UroToday.com) — Blue Earth Diagnostics, a Bracco company focused on molecular imaging diagnostics, announced results from an investigational clinical trial (“FALCON”) evaluating the impact of 18F-fluciclovine PET/CT imaging on the clinical management of men with biochemically recurrent prostate cancer eligible for salvage therapy. The FALCON trial is a UK-based, prospective, multi-center, open-label study […]

San Francisco, CA (UroToday.com) — Seattle Genetics, Inc. and Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for the investigational agent enfortumab vedotin and granted Priority Review for the treatment of patients with locally advanced or metastatic urothelial cancer who have received a PD-1/L1 inhibitor and who have […]

Alicia Morgans: Hi, I’m thrilled to be here today at APCCC 2019 with Professor Ros Eeles, who is a professor of Oncogenetics at the Institute of Cancer Research in London. Thank you so much for being here. Ross Eeles: It’s a pleasure. Alicia Morgans: Wonderful. So you gave a lovely talk, trying to help us as […]

William K. Oh: Thank you. Thank you Silke and Aurelius for the invitation. I was working on my slides until about 10 minutes ago. These are my disclosures. Just an update on the cancer death rates in the US and some of you have seen this. I’ve put up these slides for the last decade. […]

Felix Feng: Thank you for the introduction and I’d like to thank Silke and Aurelius for inviting me to present. So, here are my disclosures. None are directly relevant to today’s talk. I want to begin with a brief overview. Over 1.2 million patients are diagnosed with prostate cancer worldwide each year. This is something […]

Christopher Evans: Thank you also Silke and Aurelius for the invitational. I’ve not made it down the Rhine swim yet. I’m hoping to be able to accomplish that. I was asked to talk about PSA recurrence or persistence after prostatectomy. These are my disclosures and I want to thank Darya Toki who was a fellow […]

An Open-label, Single-arm, Single-center, Phase II Study to Evaluate the Efficacy and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate for Injection in Subjects With HER2-negative Metastatic or Unresectable Urothelial Cancer Condition: Urothelial Carcinoma Intervention: Drug: RC48-ADC Purpose: This study will evaluate the efficacy and safety of intravenous RC48-ADC in patients with locally advanced or […]

A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer Condition: Urothelial Carcinoma Intervention: Drug: RC48-ADC Purpose: This study will evaluate the efficacy and safety of intravenous RC48-ADC in patients with HER2 overexpressing locally advanced or metastatic urothelial cancer. […]

A Phase 1b, Multicenter, Two-Part, Open-Label Study of DS-8201a, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), in Combination With Nivolumab, an Anti-PD-1 Antibody, for Subjects With HER2-expressing Advanced Breast and Urothelial Cancer Condition: Breast Cancer, Urothelial Carcinoma Intervention: Drug: Trastuzumab deruxtecan (DS-8201a) Drug: Nivolumab Purpose: This is a study of DS-8201a, which […]